OxiGENE updates on Zybrestat evaluating Falcon trial
The updated data showed that the median time to progression for patients receiving Zybrestat plus bevacizumab and chemotherapy was 9.5 months, compared with a median time to progression
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.